, , , , , ,

What is the optimal approach to targeting BRAF V600E, HER2 overexpression, and KRAS G12C in patients with metastatic CRC?

Faculty: John Strickler, MD
Disclosures

Faculty

John Strickler, MD
Professor of Medicine
Co-leader, Duke Cancer Institute Molecular Tumor Board
Duke University

Discover more from OmniOncology.net

Subscribe now to keep reading and get access to the full archive.

Continue reading